(RTTNews) – Treace Medical Concepts, Inc. (TMCI), a medical technology company, announced that it will highlight new product additions and present clinical data at the American Orthopaedic Foot & Ankle Society (AOFAS) Annual Meeting in Seattle, Washington, from September 16-19, 2026.
Treace Medical Concepts focuses on treating bunions and other foot & ankle conditions.
Approximately 67 million Americans are affected by bunions, a complex three-dimensional deformity linked to midfoot joint instability, with about 1.1 million people eligible for surgical treatment each year, per company estimates.
Portfolio Overview
Treace’s patented Lapiplasty 3D Bunion Correction System is designed to correct the bunion deformity in three dimensions and stabilise the underlying joint instability.
Treace also offers the Adductoplasty Midfoot Correction System for midfoot deformities, the Nanoplasty and Percuplasty systems for minimally invasive bunion correction, and the SpeedMTP 1st MTP Fusion System.
According to the company, the latest additions to Treace’s 3D bunion correction portfolio include,
– Lapiplasty Lightning System, an instrumentation system paired with SpeedTMT implant technology, designed to enhance surgeon control during 3D bunion correction while reducing procedural steps.
– Tailorplasty MIS Tailor’s Bunion System, a minimally invasive surgical solution for tailor’s bunions, or bunionettes, affecting an estimated 5% to 10% of adults.
– Treace X-ray App, a cloud-based software that enables surgeons to perform foot and ankle radiographic measurements directly from X-rays.
Treace’s midfoot and hindfoot offerings include:
– SuperBite Fully-Threaded Compression Screws, a system of self-drilling screws designed to streamline fusion and osteotomy procedures across forefoot, midfoot, and hindfoot applications.
– HyperPlate XM Dynamic Compression Locking Implant, a fixation system combining locking screws and dynamic compression to support fusion in larger midfoot and hindfoot bones.
– CartiBlaster Powered Joint Prep Instrument, a single-use instrument designed for controlled cartilage removal and joint preparation in midfoot and hindfoot fusion procedures.
– VitaFuse Bioactive Glass Graft, a synthetic bone graft technology that expands Treace’s biologics portfolio, which also includes the tissue-based CortiFuse graft and procedure-specific wedges.
In addition, results unveiling the clinical performance of Treace technologies in the 5-year ALIGN3D Lapiplasty, MTA3D Adductoplasty and SPRINT SpeedPlate studies will be presented during the AOFAS Annual Meeting.
Scheduled clinical presentations include,
– The ALIGN3D Lapiplasty clinical study podium presentation, titled “Five-Year Analysis of a Prospective Multicenter Study of Triplanar Tarsometatarsal Arthrodesis With Early Weightbearing: Radiographic, Clinical and Patient-Reported Outcomes”.
– The MTA3D Adductoplasty clinical study podium presentation titled “Radiographic and Patient-Reported Outcomes Following Combined Metatarsus Adductus and Hallux Valgus Correction with Early Weightbearing: 2-year Interim Results of a Multicenter Prospective Study”
“We are excited to showcase our expanding portfolio”, said John T. Treace, CEO, founder and chairman of Treace.
TMCI has traded between $1.17 and $7.60 over the last year. The stock closed Tuesday’s trade at $4.58, down 1.08%.
For more biotechstock news visit www.rttnews.com
